Double-Blind, Placebo-Controlled, Randomized Clinical Trial Demonstrates Telomerase Activator TA-65 Decreases Immunosenescent CD8+CD28- T Cells in Humans

TA-65 is a small molecule telomerase activator extracted from Astragalus species. A previous observational study suggested that decreased the number of immunosenescent cells in healthy subjects. Here we examined impact much larger randomized, double-blind, and placebo-controlled study. This aims to evaluate effects on senescent CD8+CD28- T was placebo-controlled, multi-arm parallel trial 500 Subjects, clinical staff, primary outcome assessors were blinded until database lock. total volunteers randomly allocated, 100 subjects each, into one five groups; placebo, (100 Units) qd, (250 (500 or b.i.d. Change immunosenescence biomarker after nine months measured. The intention-to-treat analysis measure included all randomized (n = 500). Per-protocol measured 93% 424). Multilevel revealed significant decrease with intervention compared placebo group (p<0.05). Intervention by units 250 qd led decrement 28 cells/μl, while 22 cells/μl; intake an increment 4.38 cells/μl. None serious adverse events (9) deemed related unlikely be product. Adverse (AEs), ranging mild moderate severity were, observed 34.6% Oral significantly cells.